Reversed phase UHPLC/ESI-MS determination of oxylipins in human plasma: a case study of female breast cancer
The ultrahigh-performance liquid chromatography-mass spectrometry (UHPLC/MS) method was optimized and validated for the determination of oxylipins in human plasma using the targeted approach with selected reaction monitoring (SRM) in the negative-ion electrospray ionization (ESI) mode. Reversed phase UHPLC separation on an octadecylsilica column enabled the analysis of 63 oxylipins including numerous isomeric species within 12-min run time. The method was validated (calibration curve, linearity, limit of detection, limit of quantification, carry-over, precision, accuracy, recovery rate, and matrix effect) and applied to 40 human female plasma samples from breast cancer patients and age-matched healthy volunteers (control). Thirty-six oxylipins were detected in human plasma with concentrations above the limit of detection, and 21 of them were quantified with concentrations above the limit of quantitation. The concentrations determined in healthy controls are in a good agreement with previously reported data on human plasma. Quantitative data were statistically evaluated by multivariate data analysis (MDA) methods including principal component analysis (PCA) and orthogonal partial least square discriminant analysis (OPLS-DA). S-plot and box plots showed that 13-HODE, 9-HODE, 13-HOTrE, 9-HOTrE, and 12-HHTrE were the most upregulated oxylipin species in plasma of breast cancer patients.
KeywordsOxylipins Eicosanoids UHPLC/MS Breast cancer Statistical analysis Human plasma
We would like to acknowledge the help of Tereza Hrnčiarová with the statistical analysis.
This work was supported by ERC CZ project No. LL1302 sponsored by the Ministry of Education, Youth and Sports of the Czech Republic.
Compliance with ethical standards
The study was approved by the institutional ethical committee. All patients and healthy volunteers signed informed consent.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Pelengaris S, Khan M. The molecular biology of cancer: a bridge from bench to bedside. 2nd ed. Oxford: Wiley-Blackwell; 2013.Google Scholar
- 5.Cifkova E, Lisa M, Hrstka R, Vrana D, Gatek J, Melichar B, et al. Correlation of lipidomic composition of cell lines and tissues of breast cancer patients using hydrophilic interaction liquid chromatography/electrospray ionization mass spectrometry and multivariate data analysis. Rapid Commun Mass Spectrom. 2017;21:253–63.CrossRefGoogle Scholar
- 9.Melichar B, Konopleva M, Hu W, Melicharova K, Andreeff M, Freedman RS. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-g expression. Gynecol Oncol. 2004;93:149–54.CrossRefGoogle Scholar
- 23.Komaba JJ, Matsuda D, Shibakawa K, Nakade S, Hashimoto Y, Miyata Y, et al. Development and validation of an online-two-dimensional reversed-phase liquid chromatography-tandem mass spectrometry method for the simultaneous determination of prostaglandin E2, F2α, and 13,14-dihydro-15-keto prostaglandin F2α levels in human plasma. Biomed Chromatogr. 2009;23:315–23.CrossRefGoogle Scholar
- 27.Agency EMA. Committee for Medicinal Products for Human Use (CHMP) [Internet]. European medicines agency. 2011. Available from: https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chm. Accessed 10 July 2018.
- 28.Food U, Administration D. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville. 2001.Google Scholar